DIRS.INFO The most relevant business & tech news

☆ Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
▼ + stars: | 2024-04-17 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

GLP-1 drugs were originally developed to treat type 2 diabetes. Drugmakers are discovering the injections may also aid weight loss, heart issues, and sleep apnea. AdvertisementAnother new indication for injectable GLP-1 drugs: better sleep. On Wednesday, drugmaker Eli Lilly announced positive results from a large, phase-3 clinical trial, testing Zepbound (the drug name for tirzepatide) as a treatment for sleep apnea. Related storyAlready, GLP-1 drugs have been indicated for the treatment of:ObesityHeart diseaseAdvertisementIn clinical trials, GLP-1 drugs have also shown some promise for treating other conditions, including:Non-alcoholic fatty liver diseaseAddictionDepressionParkinson's and Alzheimer'sCancerThese breakthroughs may be tied to the gut-brain connectionScientists think that the main reason GLP-1 drugs work well is because of their effect on our body's gut-brain connection.

Persons: —, drugmaker Eli Lilly, Eli Lilly, KATERYNA, Daniel Drucker, GLP, Eric Topol Organizations: Service, Food and Drug Administration, American Diabetes Association, University of Toronto

☆ Promise of Eli Lilly's weight-loss drug for sleep apnea adds another reason to own the stock
▼ + stars: | 2024-04-17 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Eli Lilly said it plans to ask U.S. regulators to expand Zepbound's label to include obstructive sleep apnea, or OSA, later this year. Shares of Eli Lilly have ridden the GLP-1 craze to new heights over the past few years. The current standard of care for obstructive sleep apnea is positive airway pressure, or PAP, machines, which help keep patients' airways open while they sleep. Analysts projected obstructive sleep apnea revenue of $3 billion. An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City on Dec. 11, 2023.

Persons: Eli Lilly, Zepbound, it's, Mounjaro, Lilly, Jim Cramer, Jim, Eli Lilly YTD, Morgan Stanley, Jim Cramer's, Eli Lilly’s, Brendan Mcdermid Organizations: Novo Nordisk, GLP, OSA, Mayo, U.S, CNBC, Cleveland Clinic, National Council, Aging, Deutsche Bank, American Diabetes Association, Novo Nordisk's Ozempic, Bank of America Locations: U.S, Novo, New York City

☆ Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Eli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two late-stage clinical trials. Zepbound was more effective than a placebo at reducing the severity of obstructive sleep apnea, or OSA, in patients with obesity after a year, according to preliminary data from both trials. Eli Lilly previously announced that the FDA granted Zepbound "fast track designation" for patients with moderate-to-severe OSA and obesity. Zepbound has slipped into shortages since receiving approval in the U.S. for weight management in November.

Persons: Eli Lilly’s, Eli Lilly, Zepbound, Dr, Jeff Emmick, Eli Lilly's Organizations: U.S . Food, Drug Administration, FDA, OSA Locations: New York City, U.S

☆ Stocks making the biggest moves midday: United Airlines, Travelers, Abbott Laboratories and more
▼ + stars: | 2024-04-17 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

Quarterly revenue came in at $12.54 billion, topping an LSEG estimate of $12.45 billion. Travelers said it generated $4.69 in earnings per share on $10.18 billion in revenue. Interactive Brokers — Shares popped 3% after Interactive Brokers posted quarterly results that came in slightly ahead of Wall Street's expectations. J.B. Hunt posted earnings of $1.22 per share on $2.94 billion in revenue. Alcoa is set to report earnings after the bell.

Persons: LSEG, Eli Lilly, ASML, Hunt, Kate Spade, Abbott, Joe Biden's, Jefferies, —, Jesse Pound, Hakyung Kim, Pia Singh, Michelle Fox, Alex Harring, Sarah Min Organizations: United Airlines —, Travelers Companies, Travelers, U.S, Interactive, Hunt Transport Services, The New York Times, Federal Trade Commission, Versace, Capri Holdings, Autodesk —, Autodesk, Bancorp — U.S, Bancorp, Abbott Laboratories, FactSet, Alcoa Locations: China

☆ Weight loss drug Zepbound may help people with obstructive sleep apnea, drugmaker says
▼ + stars: | 2024-04-17 | by ( Jen Christensen | ) edition.cnn.com time to read: +4 min

CNN —Zepbound, a popular weight loss drug, also seems to help people with obstructive sleep apnea, drugmaker Eli Lilly said Wednesday. Based on results from trials in people with sleep apnea, the company said it plans to submit the material to the US Food and Drug Administration to potentially expand the use of Zepbound for obstructive sleep apnea. Obstructive sleep apnea is a disorder that causes people to briefly stop breathing while they are sleeping, sometimes several times an hour. While people are more at risk for obstructive sleep apnea as they get older, it often develops when people gain weight and have overweight or obesity. Some doctors have been prescribing the weekly injection off label to people with obstructive sleep apnea, and Lilly has been testing the drug for obstructive sleep apnea since June 2022.

Persons: CNN —, Eli Lilly, Lilly, didn’t, Dr, Sanjay Gupta, CNN’s Meg Tirrell, Amanda Sealy Organizations: CNN, Food and Drug Administration, World Health, US Food and Drug Administration, CNN Health, American Diabetes Association

☆ Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA says
▼ + stars: | 2024-04-17 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Most doses of Eli Lilly 's highly popular weight loss drug Zepbound and diabetes counterpart Mounjaro will be in short supply through the second quarter of this year as demand jumps, according to an update on the Food and Drug Administration's drug shortage database on Wednesday. All doses of Zepbound and Mounjaro besides the 2.5-milligram versions of both treatments are in a shortage. "We recognize this situation may cause a disruption in peoples' treatment regimens and areworking with purpose and urgency to help meet the surge in demand," an Eli Lilly spokesperson said in a statement to CNBC. The company expects its investments in manufacturing and supply capacity "to progressively increase production of our medicines throughout 2024 and beyond," they added.

Persons: Eli Lilly’s, Eli Lilly Organizations: Food, Novo Nordisk, CNBC Locations: New York City, U.S

☆ If you're worried about a correction and over-invested in Nvidia, replace it with these steady growth stocks instead
▼ + stars: | 2024-04-16 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Investors who are concerned they're overexposed to Nvidia could replace the name with these steady growth stocks instead, according to Trivariate Research's Adam Parker. "If NVDA reports that demand is still robust as far as the eye can see, owning AI-exposed semiconductors remains prudent," Parker said. "For those looking to hedge their aggressive AI-semiconductor bets, this group appears prudent," Parker wrote. Berkshire Hathaway surfaced as a large cap growth stock with low correlation to Nvidia , that's also able to beat the market. Charles Schwab was another large cap growth stock with low correlation to Nvidia.

Persons: Trivariate Research's Adam Parker, Parker, Berkshire Hathaway, that's, Eli Lilly, Charles Schwab Organizations: Nvidia, Citi, Waste Management, Emerson Locations: Berkshire

☆ Stocks give up early gains — Here's why a busy week of earnings is good news for investors
▼ + stars: | 2024-04-15 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. There is nothing markets hate more than uncertainty, which is why stocks struggled to hold onto their early gains. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Morgan Stanley, Goldman Sachs, Charles Schwab bode, Eli Lilly, It's, Jim Cramer's, Jim Organizations: CNBC, Dow Jones, Abbott Laboratories, Jim Cramer's Charitable Locations: East

☆ 10 things to watch in the stock market Friday, including bank earnings and portfolio stock price target bumps
▼ + stars: | 2024-04-12 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

The bank reports $1.26 in earnings per share vs. $1.11 expected. A round of price target increases on Constellation Brands after its strong quarter and upside guide Thursday. Following the release and conference call, we reiterated our buy-equivalent 1 rating on shares and raised our price target to $300 from $270. A couple more price target cuts on Tesla . BMO starts coverage on the Novo Nordisk shares with a buy-equivalent outperform rating and a $163 per share price target.

Persons: Wells Fargo, Jefferies, Rosenblatt, Wells, Wedbush's Dan Ives, robotaxi, Eli Lilly, Jim Cramer's, Jim Cramer, Jim Organizations: Bank, JPMorgan, Citigroup, Constellation Brands, BMO, Devices, Arista Networks, Citi, EV, Boeing, Novo Nordisk, Jim Cramer's Charitable, CNBC Locations: China, Tesla, Wells Fargo

☆ EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts
▼ + stars: | 2024-04-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

European Union drug regulators found no evidence that highly popular weight loss and diabetes drugs such as Wegovy and Ozempic are linked to an increased risk of suicidal thoughts and self-injury, the regulator said Friday. The review examined several drugs from Novo Nordisk , including Wegovy and Ozempic. Clinical trials from Novo Nordisk and Eli Lilly have not demonstrated a link between GLP-1s and suicidal thoughts. The probe also included other active ingredients in older weight loss and diabetes drugs, including dulaglutide, exenatide and lixisenatide. Results from another study conducted by the agency also did not support a link between GLP-1 drugs and the risk of suicidal thoughts.

Persons: Eli Lilly, couldn't, Liraglutide Organizations: Novo Nordisk, European Union, European Medicines Agency, U.S . Food, Drug Administration, EMA, Icelandic Medicines Agency Locations: London, Britain, Novo, U.S, GLP, Wegovy, Ozempic

☆ Eli Lilly's top-selling drug last year is softening. But it may not matter for the stock
▼ + stars: | 2024-04-12 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +5 min

Sales of some Eli Lilly drugs — including its best-selling product last year — appear to be softening, according to Wall Street analysts. JPMorgan flagged similar trends for Trulicity, which led all Lilly drugs with $7.13 billion in sales for all of 2023. The thesis is predicated on Eli Lilly growing faster than the broader pharmaceutical industry for years to come. Over the past three years, shares of Eli Lilly have soared nearly 300%, compared with a 24% gain for the S & P 500 . A box of the drug trulicity, made by Eli Lilly Pharmaceutical, sits on a counter at a pharmacy in Provo, Utah, January 9, 2020.

Persons: Eli Lilly, Wells, Lilly, Mounjaro, Jim Cramer, tirzepatide, Zepbound, Eli Lilly's, Novo, Wegovy, drugmaker, Jim Cramer's, Jim, Eli Lilly Pharmaceutical, George Frey Organizations: Wall Street, JPMorgan, Club, Novo Nordisk, Novo, BMO Capital Markets, Drug Administration, FDA, The Club, CNBC Locations: Wells Fargo, Trulicity, Tirzepatide, Danish, Lilly, Provo , Utah

☆ Cramer says stocks that pulled back Tuesday still 'have everything going for them'
▼ + stars: | 2024-04-09 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer reviewed Tuesday's market action, saying stocks that saw losses — like Nvidia and Eli Lilly — remain winners but had simply run too much. "The stocks that pulled back today have everything going for them, except that they've already run so much that they've become vulnerable," he said. Cramer used Nvidia , one of his favorite stocks, as an example. He also suggested tax season played a role in deciding Tuesday's winners and losers. "What a terrific time to take some profits of winning stocks to pay for the stocks' gains," Cramer said.

Persons: CNBC's Jim Cramer, Eli Lilly —, they've, Cramer, Tuesday's, Gaudi, Blackwell, Eli Lilly, he'd, you've Organizations: Nvidia, Intel Locations: Germany

☆ Modelo maker Constellation Brands is primed for market share gains but we still see one issue with the company
▼ + stars: | 2024-04-07 | by ( Paulina Likos | ) www.cnbc.com time to read: +7 min

Constellation Brands stock is looking like it could be ready to break out, with its strong beer business well-positioned for market share gains in the upcoming fiscal year. Morgan Stanley anticipates Constellation to continue gaining market share at the expense of Bud Light during this period. Since Constellation tends to boast industry-leading results in its beer business, we're confident it will deliver strong numbers again next week. Over the past few years, Constellation has been trying to boost sales in its wine and spirits business — shifting from lower-priced brands to more premium names. While wine and spirits make up a small part of Constellation's overall business, Jim has said it must go.

Persons: It's, Jim Cramer, Morgan Stanley, Jeff Marks, Jim, Bud Light, Marks, Piper Sandler, Newlands, Kim Crawford, Eli Lilly, Elliott, Jim Cramer's, Justin Sullivan Organizations: Constellation Brands, Anheuser, Busch Inbev, Modelo, Nielsen, Cinco de Mayo, Bud Light, Constellation, Piper, Elliott Investment Management, CNBC Locations: Corona, Pacifico, U.S, GLP, Modelo, San Rafael , California

☆ Here are Friday's biggest analyst calls: Apple, Tesla, Netflix, Marvell, Ollie's, Snowflake, Eli Lilly, Krispy Kreme & more
▼ + stars: | 2024-04-05 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

"We are raising our YE'24 NFLX target price $65 to a street-high $765 driven primarily by a combo of higher '24 and beyond subscriber/ARPU forecasts." "We are upgrading Ollie's Bargain Outlet to a Buy from a Hold rating while raising our price target to $90 from $80, implying 26% upside from current levels." We cut our price target from $2 to $1, still giving ATUS the highest multiple in Cable as optionality. "We are raising our already Street High $330 YE'24 target price $60 to $390 driven primarily by higher premium and to a lesser extent ad supported ARPU forecasts." Jefferies adds Pepsi to the franchise picks list Jefferies said it sees opportunity internationally for Pepsi and raised its price target to $209 per share from $199.

Persons: Marvell, it's, Bernstein, Mizuho, Wells, Piper Sandler, Krispy, JPMorgan, Eli Lilly, LLY, Stifel, Rosenblatt, Snowflake, Jefferies, underperform KBW, Daiwa, Tesla, KBW, Monness Crespi Hardt Organizations: Netflix, Bank of America, Apple, Amazon Web Services, RBC, Eaton, Piper, JPMorgan, Technologies, Cable, Spotify, BMO, Royal Bank, Pepsi, Fox, Fox News, Digital, Citi, Express, American Express Locations: NY, McDonald's, USA, Toronto, Snowflake, U.S

☆ The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
▼ + stars: | 2024-04-04 | by ( William Edwards | ) www.businessinsider.com time to read: +5 min

Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing. Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period. Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming. Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said. 4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.

Persons: Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly Organizations: VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma Locations: Tema, GLP, Danish, it's

☆ Elon Musk’s X is back to giving out free blue checks. It’s no surprise they were a tough sell
▼ + stars: | 2024-04-04 | by ( Clare Duffy | ) edition.cnn.com time to read: +5 min

New York CNN —It appears that Elon Musk has finally (mostly) given up on trying to make paid blue checks on X a thing. The return of the free blue check may be a sign that the blue check subscription business hasn’t panned out the way that Musk hoped. Musk’s purge of legacy blue checks was a messy, months-long process. And when anyone could buy a blue check, it was no longer an exclusive symbol that conferred some kind of status. Within hours of the unpaid blue checks reappearing, users were sharing advice about how to ensure they didn’t show up on their profiles.

Persons: Elon Musk, Musk, —, hasn’t, ”, Jason Goldman, Twitter’s, Eli Lilly, Eli Lilly’s, Stephen King, LeBron James, Matt Navarra, ” Goldman, X, “ Dear Elon Organizations: New, New York CNN, Twitter, Nintendo, Elon Locations: New York

☆ Diabetes drug similar to Ozempic helped slow progression of Parkinson's disease in small trial
▼ + stars: | 2024-04-04 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson's disease, too. But more research is needed to determine whether newer iterations of GLP-1s from Novo Nordisk and Eli Lilly may also help Parkinson's patients. The trial followed 156 people with early Parkinson's disease for a year. But one group was given an additional daily injection of Sanofi's drug, while the other was given a placebo. But use of Sanofi's drug was associated with an increased risk of gastrointestinal side effects, which are common across all GLP-1s.

Persons: Eli Lilly, Sanofi, drugmaker Organizations: Sanofi, Novo Nordisk, The New England, French Ministry of Health, Prevention, CNBC Locations: Novo, France, The

Hedge fund managers gathered Wednesday at the 2024 Sohn Investment Conference in New York to share their best investment ideas. It kicked off with "Next Wave Sohn," a session that features ideas from rising stars within the hedge fund industry. Endocrinology is an $8 billion market, but the cumulative market size, including the company's future therapy targets, is upward of $200 billion, which includes estimates for future obesity drugs, the investor said. It has CA$75 billion market cap with an "unbelievable record of success," according to the investor. The short seller noted that the company has a $5 billion market cap with about $4.8 billion of debt.

Persons: Sohn, Eric Wolff, Wolff, Michelle Ross, Cushing, Ross, Eli Lilly, Crinetics, XBI, Nikhil Daftary, Alimentation, Daftary, Chris Drose, Nate Koppikar, Fahmi Quadir Organizations: Investment, Gumshoe Capital Management Investment, Pason Systems Energy, Pason Systems, Gumshoe Capital Management, StemPoint, Pharmaceuticals, Crinetics Pharmaceuticals, StemPoint Capital, Endocrinology, Novo Nordisk, P Biotech, NK Capital Investment, NK Capital, Starbucks, McDonalds, Bleecker Street Capital, Orso Partners, Justice Department, Federal Trade Commission, Safkhet, Global Education Locations: New York, Canada, U.S

☆ ‘The Matrix’ has a fifth film in the works and, no, this is not a simulation
▼ + stars: | 2024-04-03 | by ( Alli Rosenbloom | ) edition.cnn.com time to read: +2 min

The beloved “Matrix” movie franchise is expanding with an upcoming fifth installment, with the film’s original co-writer and co-director Lana Wachowski leading the charge as executive producer. According to a press release from the film’s studio Warner Bros. Motion Picture Group sent on Wednesday, Oscar-nominated screenwriter Drew Goddard will write and direct the film alongside his producing partner Sarah Esberg. (Warner Bros. Motion Picture Group is a subsidiary of CNN’s parent company, Warner Bros. “The Matrix” premiered in 1999 and stars Reeves, Laurence Fishburne, Hugo Weaving and Carrie-Anne Moss. It went on to win four Academy Awards and spawned three sequels, including “The Matrix Reloaded” and “The Matrix Revolutions” in 2003, and “The Matrix Resurrections” in 2021.

Persons: Lana Wachowski, Oscar, Drew Goddard, Sarah Esberg, Jesse Ehrman, Warner, Goddard “, Lana, Lilly, Wachowski, Keanu Reeves, Reeves, Goddard, ’, Laurence Fishburne, Hugo Weaving, Carrie, Anne Moss Organizations: CNN, Warner Bros, Warner Bros ., Motion Locations: ”

Post's price target increase is in line with his move on the GAAP price-to-earnings multiple to 22 from 21. — Alex Harring 6:39 a.m.: Melius moves to sidelines on Boeing Boeing has too many areas of concern, Melius Research warned. Analyst Robert Spingarn downgraded the plane maker to hold from buy and slashed his price target by $71 to $209. Analyst Filippo Falorni upgraded the cosmetics stock to buy from neutral and hiked his price target by $15 to $175. Analyst Brennan Hawken downgraded the investment asset manager to neutral from buy and cut his price target by $5 to $135.

Persons: Grinder, Justin Post, Meta, — Alex Harring, Eli Lilly, Andrew Baum, Baum, Novo, Robert Spingarn, Spingarn, LSEG, Alex Harring, Filippo Falorni, Falorni, Estee Lauder, Lauder, Tom Ford, Le, Blackstone, Brennan Hawken, Hawken, JMP, Nicholas Jones, Jones, Grindr, Christopher Dendrinos, Dendrinos, — Fred Imbert Organizations: CNBC, RBC, GE, of America, Citi, Indianapolis, Boeing Boeing, Melius, Boeing, Dow Jones, Coca, Cola, Beverage, Travel, UBS, GE Vernova, New York Stock Exchange Locations: Monday's, Asia Pacific, Asia

☆ Jim Cramer says Microsoft's unbundling of Teams and Office is good news for this portfolio stock
▼ + stars: | 2024-04-02 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. "We should all expect sell-offs after a bountiful period that started in October," Jim Cramer said. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER .

Persons: Jim Cramer, Eli Lilly, Eli Lilly's, Eli Lilly's GLP, Jim, Slack, Jim Cramer's Organizations: CNBC, Citigroup, Citi, Microsoft, Club

☆ Here are Tuesday's biggest analyst calls: Nvidia, Meta, Boeing, Eli Lilly, Disney, Coca-Cola, Grindr & more
▼ + stars: | 2024-04-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +8 min

Here are Tuesday's biggest calls on Wall Street: Oppenheimer reiterates Nvidia as outperform Oppenheimer said it's sticking with its outperform rating on shares of Nvidia. Citi reiterates Eli Lilly as buy Citi said the biopharma company is "riding the GLP-1 rocket." Citi downgrades Clorox to neutral from buy Citi said that the bullish thesis for the stock has largely played out for now. Citi upgrades Estee Lauder to buy from neutral Citi said it sees a "topline inflection point" for the stock. Barclays upgrades Array Technologies to overweight from equal weight Barclays said it sees share gains for the solar company.

Persons: Oppenheimer, McCormick, Argus, Needham, it's, Nelson Peltz, Melius, Horton, Citi, Eli Lilly, Estee Lauder, ARRY, JMP, Piper Sandler, Piper, Nio, CFRA, Goldman Sachs, Goldman, Blackstone, Petco Organizations: Nvidia, JPMorgan, Disney, Boeing, Citi, Coca, MTH, RBC, GE Vernova, General Electric, Bank of America, Meta, Travel, Barclays, Eaton, MI, Olema Pharmaceuticals, UBS, Bank of, of America Locations: underperform, LEN, DHI, Asia, Eaton, 4Q23

☆ Opinion: 25 years later, ‘The Matrix’ is less sci-fi than tech reality
▼ + stars: | 2024-03-30 | by ( Opinion Rizwan Virk | ) edition.cnn.com time to read: +11 min

In 2003, Oxford philosopher Nick Bostrom imagined a “technologically mature” civilization could easily create a simulated world. With simulated worlds far outnumbering the “real” world, the likelihood that we are in a simulation would be significantly higher than not. Remember, the simulations would be so good that you wouldn’t be able to tell the difference between a physical and a simulated world. Either the signals are being beamed directly into your brain, or we are simply AI characters inside the simulation. Already, millions of humans are chatting with AI characters, and millions of dollars are pouring into making AI characters more realistic.

Persons: Virk, X, CNN — It’s, ”, Lana, Lilly Wachowski, Philip K, Dick, Tessa, Morpheus, Laurence Fishburne, Keanu Reeves, Nick Bostrom, Elon Musk, Smith, Hugo Weaving, Carrie Ann, Moss, Musk, OpenAI, it’s, Reeves ’ Organizations: Labs, MIT, Physics, Eastern, Arizona State University’s College of Global Futures, Center for Science, CNN, Apple, Trinity Locations: zenentrepreneur.com, Oxford, Silicon, Silicon Valley

☆ Reopening the Port of Baltimore could take weeks as colossal wreckage cleanup gets underway, officials say
▼ + stars: | 2024-03-30 | by ( Dalia Faheid | Aditi Sangal | ) edition.cnn.com time to read: +6 min

CNN —It could take weeks for the Port of Baltimore to reopen as an arduous cleanup process to clear the massive wreckage from this week’s catastrophic bridge collapse begins, leaving commuters and workers in limbo and supply chains in disarray, officials said. More than 1,000 engineers in Baltimore and across the country are studying the wreckage piece-by-piece to figure out the best plan to remove it. To help with this massive task, more heavy equipment is expected at the scene in the coming weeks. The port is the largest in the US for cars and light trucks, handling a record 850,000 vehicles last year, Moore said. “Our economy depends on the Port of Baltimore and the Port of Baltimore depends on vessel traffic,” Moore said Friday.

Persons: –, Francis Scott Key, Crews, “, ”, Scott Spellmon, Spellmon, Wes Moore, ” Moore, Moore, that’s, Mark Schiefelbein, Gustavo Torres, …, ” Torres, Alejandro Hernandez Fuentes, Dorlian Ronial Castillo Cabrera, Miguel Luna, Suazo Sandoval, Carlos Hernández, Hernández, Jazmin Alvarez, Lucia Zambrano, ” Zambrano, – Jose Mynor Lopez –, Isabel Franco, Lilly Ordonez, Franco Organizations: CNN, Port, US Army Corps of Engineers, Coast Guard, Maryland Gov, Workers, Authorities, CASA, AP CASA, Univision, Univision she’s Locations: Port of Baltimore, Baltimore, Maryland, America, Mexico, Guatemala, El Salvador, Honduras, Dundalk , Maryland

☆ A new Ozempic rival helps patients lose fat, but keep their muscle — the holy grail for a weight-loss drug
▼ + stars: | 2024-03-29 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +3 min

A new GLP-1 drug, pemvidutide, helped patients lose fat while guarding muscle, like exercise does. That's impressive when you compare it to existing GLP-1 drugs like Ozempic and Wegovy (semaglutide), or Mounjaro and Zepbound (tirzepatide). This is why doctors recommend patients on weight loss drugs do some strength training in tandem with their medication. Pemvidutide, like tirzepatide is a two-part drug that combines a GLP-1 drug with another drug in a single shot. "There is a growing appreciation that the quality of weight loss is as important as the quantity of weight loss," Scott Harris, Altimmune's chief medical officer, said in a release.

Persons: Drugmakers Eli Lilly, —, Drugmaker Altimmune, Altimmune, Scott Harris, Eli Lilly, FierceBiotech, Versanis Organizations: Novo Nordisk, Service Locations: Altimmune, GLP

Search resuls for: "Lilly"

25 mentions found